221 related articles for article (PubMed ID: 12679487)
1. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections.
Wapnir IL; van de Rijn M; Nowels K; Amenta PS; Walton K; Montgomery K; Greco RS; Dohán O; Carrasco N
J Clin Endocrinol Metab; 2003 Apr; 88(4):1880-8. PubMed ID: 12679487
[TBL] [Abstract][Full Text] [Related]
2. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa.
Spitzweg C; Joba W; Eisenmenger W; Heufelder AE
J Clin Endocrinol Metab; 1998 May; 83(5):1746-51. PubMed ID: 9589686
[TBL] [Abstract][Full Text] [Related]
3. Sodium/iodide-symporter: distribution in different mammals and role in entero-thyroid circulation of iodide.
Josefsson M; Grunditz T; Ohlsson T; Ekblad E
Acta Physiol Scand; 2002 Jun; 175(2):129-37. PubMed ID: 12028133
[TBL] [Abstract][Full Text] [Related]
4. Expression of sodium iodide symporter in human breast tissues.
Angelousi A; Nonni A; Kassi E; Kontzoglou K
J BUON; 2016; 21(1):53-60. PubMed ID: 27061531
[TBL] [Abstract][Full Text] [Related]
5. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents.
Patel A; Jhiang S; Dogra S; Terrell R; Powers PA; Fenton C; Dinauer CA; Tuttle RM; Francis GL
Pediatr Res; 2002 Nov; 52(5):737-44. PubMed ID: 12409522
[TBL] [Abstract][Full Text] [Related]
6. Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma.
Berger F; Unterholzner S; Diebold J; Knesewitsch P; Hahn K; Spitzweg C
Biochem Biophys Res Commun; 2006 Nov; 349(4):1258-63. PubMed ID: 16982034
[TBL] [Abstract][Full Text] [Related]
7. Radioiodide uptake and sodium iodide symporter expression in breast carcinoma.
Damle AA; Narkar AA; Badwe RA
Indian J Exp Biol; 2011 Jun; 49(6):416-22. PubMed ID: 21702220
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.
Saito T; Endo T; Kawaguchi A; Ikeda M; Katoh R; Kawaoi A; Muramatsu A; Onaya T
J Clin Invest; 1998 Apr; 101(7):1296-300. PubMed ID: 9525971
[TBL] [Abstract][Full Text] [Related]
9. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond.
Dohán O; Carrasco N
Mol Cell Endocrinol; 2003 Dec; 213(1):59-70. PubMed ID: 15062574
[TBL] [Abstract][Full Text] [Related]
10. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
Peyrottes I; Navarro V; Ondo-Mendez A; Marcellin D; Bellanger L; Marsault R; Lindenthal S; Ettore F; Darcourt J; Pourcher T
Eur J Endocrinol; 2009 Feb; 160(2):215-25. PubMed ID: 19029227
[TBL] [Abstract][Full Text] [Related]
11. Sodium iodide symporter, estrogen receptor, and progesterone receptor expression in carcinoma breast--an immunohistochemical analysis.
Tandon A; Shrivastava A; Kumar A; Prayaga AK; Sundaram C; Godbole MM
Indian J Pathol Microbiol; 2011; 54(4):745-51. PubMed ID: 22234102
[TBL] [Abstract][Full Text] [Related]
12. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue.
Upadhyay G; Singh R; Agarwal G; Mishra SK; Pal L; Pradhan PK; Das BK; Godbole MM
Breast Cancer Res Treat; 2003 Jan; 77(2):157-65. PubMed ID: 12602914
[TBL] [Abstract][Full Text] [Related]
13. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands.
Spitzweg C; Joba W; Schriever K; Goellner JR; Morris JC; Heufelder AE
J Clin Endocrinol Metab; 1999 Nov; 84(11):4178-84. PubMed ID: 10566669
[TBL] [Abstract][Full Text] [Related]
14. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid.
Wapnir IL; Goris M; Yudd A; Dohan O; Adelman D; Nowels K; Carrasco N
Clin Cancer Res; 2004 Jul; 10(13):4294-302. PubMed ID: 15240514
[TBL] [Abstract][Full Text] [Related]
15. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
[TBL] [Abstract][Full Text] [Related]
17. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
19. Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases.
Dohán O; Baloch Z; Bánrévi Z; Livolsi V; Carrasco N
J Clin Endocrinol Metab; 2001 Jun; 86(6):2697-700. PubMed ID: 11397873
[TBL] [Abstract][Full Text] [Related]
20. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
